Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium

Media Release Basel, 18 November 2019 Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer Follow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in HER2-positive early breast cancer Results from phase III FeDeriCa study confirming the non-inferiority of a fixed-dose combination of Perjeta and Herceptin administered